Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1 Baseline demographic and clinical characteristics of the study participants

From: Altered lipoproteins in patients with systemic lupus erythematosus are associated with augmented oxidative stress: a potential role in atherosclerosis

  SLE patients (n = 35) Healthy controls (n = 15) p value
Age, years, mean ± SD 40.6 ± 11.7 37.7 ± 6.1 0.244
Female, n (%) 34 (97.1) 13 (86.6) 0.211
Height, cm 160. ± 7.1* 161.8 ± 6.3 0.415
Weight, kg 54.7 ± 9.5* 53.3 ± 6.5 0.620
Body mass index, kg/m2 21.3 ± 3.1* 20.4 ± 2.0 0.277
Smoking, n (%) 3 (9.4) 0 (0) 0.306
Alcohol, n (%) 1 (3.1) 0 (0) 0.681
Diabetes, n (%) 2 (5.7) 0 (0) 0.486
Hypertension, n (%) 11 (31.4) 0 (0) 0.011
Dyslipidemia, n (%) 4 (11.4) 0 (0) 0.227
SLE duration, years 12.1 ± 7.6   
ESR, mm/hour 25.4 ± 22.5   
SLEDAI-2 K 4.26 ± 4.24   
C3 (mg/dL) 75.4 ± 23.6   
C4 (mg/dL) 12.6 ± 7.2   
Treatment, n (%)
 Corticosteroids 35 (100) 0 (0)  
 Corticosteroid dose (prednisolone equivalent), mg/day 7.8 (8.4) 0 (0)  
 Hydroxychloroquine 31 (88.6) 0 (0)  
 Azathioprine 2 (5.7) 0 (0)  
 Methotrexate 1 (2.9) 0 (0)  
Statins 2 (5.7) 0 (0)  
ACE inhibitors 2 (5.7) 0 (0)  
ARB 2 (5.7) 0 (0)  
Aspirin 1 (2.9) 0 (0)  
  1. *Available for 32 patients
  2. ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, ESR erythrocyte sedimentation rate, SLE systemic lupus erythematosus, SLEDAI-2 K, SLE disease activity index 2000